CXCL1 and colorectal carcinoma: To investigate the resistance performance of our proposed 9 candidate drugs against the state-of-the-art alternative receptors for CRC by molecular docking, we considered the top-ranked 8 independent receptors (MYC, CDK1, CXCL1, CXCL8, CXCL12, TIMP1, AURKA, and TOP2A) published by others in different 36 articles for CRC (see Additional file 1: Table S1), where the receptor CXCL8 was common with our proposed receptor.